

Effect of Usnic Acid on *Candida orthopsilosis* and *C. parapsilosis*

Regina Helena Pires,^a Rodrigo Lucarini,^b and Maria Jose Soares Mendes-Giannini^a

Universidade Estadual Paulista, UNESP, Araraquara, SP, Brazil,^a and Universidade de Franca, Franca, SP, Brazil^b

The activity of usnic acid against *Candida orthopsilosis* and *Candida parapsilosis* on planktonic and biofilm conditions was investigated by using a broth microdilution and microplate methods. Potent *in vitro* activities against different *Candida* species were obtained. The metabolic activity of sessile cells of *C. parapsilosis* complex was reduced by 80% at four times the 80% inhibitory concentration. The *in vitro* studies support further efforts to determine whether usnic acid can be used clinically to cure patients with *Candida* infections.

Among the *Candida* strains reported to cause human diseases, more than 17 different species have been identified (9, 19). Many of these species have been observed to occur in the hemodialysis setting and/or to exhibit innate or acquired resistance to one or more established antifungal agents (4, 12, 13, 16, 21). In addition, the use of molecular identification methods has resulted in the identification of new species within larger species complex such as *Candida orthopsilosis* and *Candida metapsilosis* within the *Candida parapsilosis* complex (23). In particular, the percentage of isolates of *C. orthopsilosis* has been much higher in the *C. parapsilosis* complex isolates in Latin America (12.7%) (11).

The small number of drugs available for fungal treatment encourages the search for new chemotherapeutic agents. Usnic acid (2,6-diacetyl-1,2,3,9b-tetrahydro-7,9-dihydroxy-8,9b-dimethyldibenzofuran-1,3-dione), a secondary lichen metabolite, is known to possess antimicrobial properties in addition to antiviral, antiprotozoal, antiproliferative, anti-inflammatory, and analgesic activity (10).

With respect to antimicrobial properties, usnic acid has activity against a number of planktonic Gram-positive bacteria and also has the capacity to control biofilm formation by *Staphylococcus aureus* and *Pseudomonas aeruginosa* (8). Indeed, the mechanism of action expressed by usnic acid is still unknown. According to the same study (8), usnic acid could inhibit quorum sensing in *P. aeruginosa* biofilms.

Usnic acid has been tested against some *Candida* species, but there is no published data concerning its activity against the newly described species within the *C. parapsilosis* complex. Thus, we tested usnic acid in both planktonic or biofilm modes of growth in *C. orthopsilosis* and *C. parapsilosis*.

Six isolates of *C. parapsilosis* complex able to form biofilms were collected from a hemodialysis unit located in the state of São Paulo, Brazil, between March 2006 and March 2007 obtained from 110 samples of water that were selected for testing. The identification of *C. parapsilosis* and *C. orthopsilosis* was confirmed by molecular methods as described previously (23). The MIC for usnic acid of planktonic *C. parapsilosis* complex cultures was determined in RPMI 1640 buffered with morpholinepropanesulfonic acid (MOPS) (both from Sigma Chemical Co., St. Louis, MO) using a broth microdilution method adapted from the CLSI approved standard (M27-A3) (6). Briefly, the usnic acid (Sigma) was dissolved in 5% (vol/vol) in dimethyl sulfoxide (DMSO) (Sigma) that had been filter sterilized through a 0.22- μ m-pore-size filter (Millipore, Billerica, MA) and added to the growth medium to obtain final concentrations ranging from 0.48 μ g/ml at 1,000 μ g/

ml. Yeast cells were then added to each well at the final concentration of 1×10^6 cells/ml (2, 5, 15). The microtiter trays were incubated at 35°C for 48 h. Afterwards, IC₅₀ and IC₈₀ values (the lowest concentrations that inhibit 50% and 80% of the yeast growth in comparison to untreated control, respectively), were determined using a spectrophotometer at 492 nm. Controls containing antimicrobial agents in broth without fungal inocula were included. Amphotericin B (final concentration of 0.0156 to 16 μ g/ml) and the *C. parapsilosis* ATCC 90018 strain were used as quality controls.

After the MIC assay, minimal fungicidal concentrations (MFCs) were determined by plating 10 μ l of the material in each of the clear wells onto Sabouraud dextrose agar (SDA) (Difco) plates. The MFC was defined as the lowest concentration yielding no growth following incubation at 37°C for 48 h.

The MICs for sessile (biofilm) cells (SMICs) were determined by a microtiter plate assay as described previously (20). Briefly, each well on a 96-well microtiter plate was filled with 100 μ l of RPMI 1640 containing 10^6 cells of an overnight culture. After 24 h of incubation at 37°C, the biofilms were washed three times with sterile phosphate-buffered saline (PBS) (10 mM potassium phosphate, 0.15 M NaCl [pH 7.0]). The biofilms were exposed to 100 μ l of antimicrobial agent, and the plates were incubated for 48 h at 37°C, after which the usnic acid was removed by washing each well twice with 100 μ l PBS. Fungal viability was analyzed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma) as described previously (17). Briefly, 200 μ l prewarmed MTT solution (0.5 mg/ml) in PBS containing 0.1% glucose and 10 μ l of 10 μ M menadione was added to each well. The plates were incubated at 37°C for 30 min, and the MTT solution was removed. The yeast cells were washed once with PBS and resuspended in acid isopropanol (5% [vol/vol] 1 M HCl in isopropanol). Finally, the absorbance at 540 nm (A_{540}) was measured using a microtiter plate reader (ASYS, Eugendorf, Salzburg, Austria). The BEC₅₀ and BEC₈₀ for *Candida* biofilms were defined as the lowest drug concentration with a 50% and 80% reduction, respectively, in the

Received 21 July 2011 Returned for modification 27 August 2011

Accepted 11 October 2011

Published ahead of print 17 October 2011

Address correspondence to Regina Helena Pires, rehepi@gmail.com.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.05348-11

TABLE 1 Activities of usnic acid against *C. orthopsilosis* and *C. parapsilosis* isolates

Candida species	Antifungal activity ($\mu\text{g/ml}$) ^a					
	Planktonic growth			Biofilm growth		
	IC ₅₀	IC ₈₀	MFC	BEC ₅₀	BEC ₈₀	MBFC
<i>C. orthopsilosis</i>	1.95	7.8	125	3.9	31.2	125
<i>C. parapsilosis</i>	1.95	15.6	250	3.9	62.5	250

^a IC₅₀ and IC₈₀, concentration required for 50% and 80% inhibition in cell growth compared with the untreated controls, respectively; MFC, minimal fungicidal concentration; BEC₅₀ and BEC₈₀, 50% and 80% reduction in the metabolic activity of the biofilms compared to untreated controls, respectively; MBFC, minimum biofilm fungicidal concentration.

metabolic activity of the biofilms compared to controls (drug free). The minimum biofilm fungicidal concentration (MBFC) was defined as the concentration with A_{540} values below or equal to the background level (acid isopropanol). The antimicrobial activity of 5% (vol/vol) DMSO was also studied on a separate plate alongside the assay plate. *C. albicans* SC5314 was used as the biofilm control strain (20, 22). All experiments were performed in triplicate on three different days.

As shown in Table 1, usnic acid exhibited an anti-*Candida* effect, with IC₅₀ of 1.95 $\mu\text{g/ml}$ and IC₈₀s of 7.8 and 15.6 $\mu\text{g/ml}$. Reduction of 50% in the metabolic activities of biofilms of both *C. parapsilosis* strains (BEC₅₀) was achieved at a concentration of 3.9 $\mu\text{g/ml}$; 31.2 and 62.5 $\mu\text{g/ml}$ reduced the growth of the cells in 80% (BEC₈₀) (Table 1). In contrast, the MBFCs of usnic acid were comparable to the MFCs estimated at 125 and 250 for *C. orthopsilosis* and *C. parapsilosis*, respectively (Table 1). For these environmental isolates, *C. orthopsilosis* was more susceptible to usnic acid than the *C. parapsilosis*. The MIC values for the reference strain that was used as a positive control for amphotericin B were within the established values for the CLSI M27-A3 protocol. DMSO (5% [vol/vol]), which was used as a cosolvent in the drug suspensions, did not show anticandidal activity against *C. parapsilosis* complex grown in suspension or as a biofilm.

Based on the existing literature, usnic acid seems to be produced only in lichens and appears to be effective against a wide variety of bacterial strains, and the antifungal properties previously reported by Cardarelli et al. (3) were confirmed by the results of this study. Because of their antimicrobial activity, usnic acid has been the target of many studies for the purpose of developing phytotherapeutic options for treatment of infections (14). According to Francolini et al. (8), there was no evidence of a toxic effect of usnic acid in pharmacokinetics studies and after oral administration.

According to the values of EC₅₀, EC₈₀, BEC₅₀, and BEC₈₀ obtained for the isolates of *C. orthopsilosis* and *C. parapsilosis*, usnic acid demonstrated potent inhibitory activity against both planktonic and biofilm cells (Table 1). Furthermore, Yilmaz et al. (24) showed that usnic acid with quite low MIC values (0.15 μg per disk) was effective against 10^7 cells/ml of *Candida albicans* or *Candida glabrata*. Similarly, lower MICs (ranging from 1 to 26 $\mu\text{g/ml}$) determined by the disk diffusion method have been observed against *Bacillus subtilis* (18). One factor that may explain our results include the absence of standardized anticandidal assays for natural products. Results can be profoundly influenced by the testing method (7). Previous studies have shown that antimicro-

bial activity can be more effectively evaluated in liquid media than in solid media, since in the latter, the diffusion of drug may not be appropriate (1).

The results presented in this study are the first report of usnic acid showing *in vitro* inhibitory and fungicidal activity against environmental isolates of *C. orthopsilosis* and *C. parapsilosis*. Considering also the absence of cytotoxicity and low concentrations obtained, usnic acid represents a promising area of future research. The mechanisms of its antifungal activity should be studied in order to validate the use of usnic acid as a natural antifungal product.

REFERENCES

- Al-Hiti MM, Gilbert P. 1983. A note on inoculum reproducibility: a comparison between solid and liquid culture. *J. Appl. Bacteriol.* 55:173–175.
- Braga PC, Culici M, Alfieri M, Dal Sasso M. 2008. Thymol inhibits *Candida albicans* biofilm formation and mature biofilm. *Int. J. Antimicrob. Agents.* 31:472–477.
- Cardarelli M, et al. 1997. Antimitotic effects of usnic acid on different biological systems. *Cell. Mol. Life Sci.* 53:667–672.
- Centers for Disease Control and Prevention (CDC). 2011. Vital signs: central line-associated blood stream infections—United States, 2001, 2008, and 2009. *Morb. Mortal. Wkly. Rep.* 60:243–248.
- Chami N, Bennis S, Chami F, Abousekhra A, Remmal A. 2005. Study of anticandidal activity of carvacrol and eugenol *in vitro* and *in vivo*. *Oral Microbiol. Immunol.* 20:106–111.
- Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
- Cos P, Vlietinck AJ, Berghe DV, Maes L. 2006. Anti-infective potential of natural products: how to develop a stronger *in vitro* “proof-of-concept.” *J. Ethnopharmacol.* 106:290–302.
- Francolini I, Norris P, Piozzi A, Donelli G, Stoodley P. 2004. Usnic acid, a natural antimicrobial agent able to inhibit bacterial biofilm formation on polymer surfaces. *Antimicrob. Agents Chemother.* 48:4360–4365.
- Hazen KC, Howell SA. 2007. *Candida*, *Cryptococcus*, and other yeasts of medical importance, p 1762–1788. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
- Ingólfssdóttir K. 2002. Usnic acid. *Phytochemistry* 61:729–736.
- Lockhart SR, Messer SA, Tendolkar S, Diekema DJ. 2008. Geographic distribution and antifungal susceptibility of newly described species *Candida orthopsilosis*, in comparison to the closely related species *Candida parapsilosis*. *J. Clin. Microbiol.* 46:2659–2664.
- Marriott DJ, et al. 2009. Determinants of mortality in non-neutropenic ICU patients with candidaemia. *Crit. Care* 13:R115.
- Medrano DJA, et al. 2006. Candidemia in a Brazilian hospital: the importance of *Candida parapsilosis*. *Rev. Inst. Med. Trop. São Paulo* 48:17–20.
- Molnár K, Farkas E. 2010. Current results on biological activities of lichen secondary metabolites: a review. *Z. Naturforsch C* 65:157–173.
- Nett JE, Guite KM, Ringeisen A, Holoyda KA, Andes DR. 2008. Reduced biocide susceptibility in *Candida albicans* biofilms. *Antimicrob. Agents Chemother.* 52:3411–3413.
- Nucci M, Queiroz-Telles F, Tobón AM, Restrepo A, Colombo AL. 2010. Epidemiology of opportunistic fungal infections in Latin America. *Clin. Infect. Dis.* 51:561–570.
- Nuryastuti T, et al. 2009. Effect of cinnamon oil on *icaA* expression and biofilm formation by *Staphylococcus epidermidis*. *Appl. Environ. Microbiol.* 75:6850–6855.
- Paudel B, et al. 2010. Antibacterial activities of Ramalin, usnic acid and its three derivatives isolated from the Antarctic lichen *Ramalina terebrata*. *Z. Naturforsch C.* 65:34–38.
- Pfaller MA, et al. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of *Candida* species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. *J. Clin. Microbiol.* 45:1735–1745.
- Pierce CG, et al. 2008. A simple and reproducible 96-well plate-based

- method for the formation of fungal biofilms and its application to anti-fungal susceptibility testing. *Nat. Protoc.* 3:1494–1500.
21. Qureshi AL, Abid K. 2010. Frequency of catheter related infections in haemodialysed uraemic patients. *J. Pak. Med. Assoc.* 60:671–675.
 22. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. 2002. Inhibition of *Candida albicans* biofilm formation by farnesol, a quorum-sensing molecule. *Appl. Environ. Microbiol.* 68:5459–5463.
 23. Tavanti A, Davidson AD, Gow NA, Maiden MCJ, Odds FC. 2005. *Candida orthopsilosis* and *Candida metapsilosis* spp. nov. to replace *Candida parapsilosis* groups II and III. *J. Clin. Microbiol.* 43:284–292.
 24. Yilmaz M, Türk AO, Tay T, Kivanç M. 2004. The antimicrobial activity of extracts of the lichen *Cladonia foliacea* and its (–)-usnic acid, atranorin, and fumarprotocetraric acid constituents. *Z. Naturforsch C* 59:249–254.